608 results about "Mucus" patented technology

The invention provides an application of a fermentation lactobacillus mucus strain A21196 in preparation of a product for resisting anxiety and improving memory and concentration, and belongs to the technical field of biological medicines. Animal experiments show that the fermented lactobacillus mucus strain A21196 has the effects of resisting anxiety, resisting depression, improving cognitive impairment function and improving memory concentration, and provides a new means for preventing and / or treating nerve diseases related to anxiety disorder, depression and cognitive impairment.

The invention discloses a probiotic with the depression improving effect and a microecological preparation and application thereof, and is characterized in that the probiotic comprises lactobacillus mucus PC17 with the preservation number of CGMCC No.33866, the active ingredients of the lactobacillus microecological preparation comprise thalli of the lactobacillus mucus PC17, and a preparation method of the microecological preparation comprises the following steps: adding the lactobacillus mucus PC17 into the lactobacillus mucus PC17, uniformly mixing the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17 and the lactobacillus mucus PC17 The lactic acid bacteria are inoculated into a fermentation culture medium according to a volume ratio of 1-5% to prepare the lactic acid bacteria microecological preparation, can be used for preparing antidepressant drugs, and has the advantages of being capable of promoting RIN14B cells to secrete 5-hydroxytryptamine and 5-hydroxytryptophan, reducing the levels of interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, corticosterone and corticotropin in serum, and improving the antidepressant activity of the antidepressant drugs. The levels of aminobutyric acid and brain-derived neurotrophic factors in serum are improved, and the depression-like behaviors of CUMS depression model mice are obviously improved.

The invention discloses fermented lactobacillus mucus NJ-10 and application thereof in preparation of rare ginsenoside-rich metagen through fermentation conversion, and relates to the field of probiotic fermentation. The lactobacillus fermentum NJ-10 is preserved in the China Center for Type Culture Collection on February 25, 2025, and the preservation number of the lactobacillus fermentum NJ-10 is CCTCC (China Center for Type Culture Collection) NO: M 2025300. According to the present invention, the fermentation lactobacillus mucus NJ-10 capable of producing beta-glucosidase, which is subjected to autonomous separation and identification, can be used for fermentation and conversion of ginseng stem and leaf saponin, and then is subjected to post-generation preparation in a high-temperature and high-pressure steam manner, such that the beta-glucosidase producing beta-glucosidase can be produced, and the beta-glucosidase producing beta-glucosidase producing beta-glucosidase producing beta-glucosidase producing beta-glucosidase producing beta-glucosidase can be produced. According to the method, ginseng stem and leaf saponin is converted through two-step fermentation to prepare the postbiotic fermentation product rich in rare ginsenoside, resource utilization of non-medicinal parts of ginseng is expanded, and the postbiotic fermentation product has wide application prospects in the fields of food industry, pharmaceutical industry, cosmetics, animal breeding and the like.

The invention relates to the technical field of microorganisms, and provides lactobacillus mucilaginosus for maintaining genital tract health and preventing genital tract infection and application of lactobacillus mucilaginosus. Fermented mucus lactobacillus for maintaining genital tract health and preventing genital tract infection is named as FMTA1113H and is preserved in China General Microbiological Culture Collection Center (CGMCC) on April 22, 2025, the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.34291. The invention further discloses a preparation method of the fermented mucus lactobacillus for maintaining genital tract health and preventing genital tract infection. According to the technical scheme, the problems that female genital tracts are prone to infection and relapse is prone to occurring after infection in the prior art are solved.

The invention belongs to the technical field of traditional Chinese medicine fermentation, and particularly relates to dendrobium officinale fermentation liquor with a pancreatic lipase inhibition effect and a preparation method of the dendrobium officinale fermentation liquor. The dendrobium officinale fermentation liquor is prepared by performing enzymolysis on dendrobium officinale and inoculating lactic acid bacteria for fermentation, wherein the dendrobium officinale fermentation liquor obtained by inoculating fermentation lactobacillus mucus DSM 13273 or leuconostoc mesenteroides subsp. Mesenteroides XD054 has a better pancreatic lipase activity inhibition effect.

The invention belongs to the technical field of probiotics and application thereof, and relates to a probiotic capable of reducing uric acid and a product thereof, in particular to a strain of Lentilactobacillusbuchneri strain ZD62 which is preserved in China Center for Type Culture Collection on March 14, 2024, the preservation address is Wuhan University, Wuhan, China, and the preservation number is CCTCC NO: M2024469, and the preservation number is CCTCC NO: M2024469, the preservation number is CCTCC NO: M2024469, the preservation number is CCTCC NO: M2024469, and the preservation number is CCTCC NO: M2024469. The invention relates to a compound probiotic agent, which is prepared from Lentilactobacilli buchneri strain ZD62 and Mycobacterium fermentum ZD103, and is characterized in that the Mycobacterium fermentum ZD103 is prepared from Lentilactobacilli buchneri strain ZD62; the lactobacillus buchneri ZD62 and the mucus fermentum ZD103 provided by the invention have a good characteristic of reducing uric acid.

The invention discloses lactobacillus reuteri LR69 capable of enhancing a gastric mucosal barrier and application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides a lactobacillus reuteri LR69, and the preservation number of the lactobacillus reuteri LR69 is CGMCC (China General Microbiological Culture Collection Center) No.33731. The lactobacillus reuteri LR69 is a lactobacillus reuteri LR69. The invention also provides application of the strain in preparation of food with an auxiliary protection function on gastric mucosa, and / or food with an intestinal flora regulating function, and / or a product for relieving gastritis, and / or food with an immunity enhancing function, and / or a bacteriostatic agent. The invention further discloses a food with an auxiliary protection function on gastric mucosa, a food with an intestinal flora regulating function, a product for relieving gastritis, a food with an immunity enhancing function, a bacteriostatic agent and an in-vitro bacteriostasis method based on the strain. The lactobacillus reuteri LR69 disclosed by the invention can effectively assist in protecting gastric mucosa, regulating intestinal flora, relieving gastritis, enhancing immunity and realizing broad-spectrum bacteriostasis.

The heating apparatus for removing mucus comprises a face mask and a chest cover. The face mask may be adapted to be worn adjacent to a face and may retain water between the face mask and the face. The chest cover may be adapted to be worn adjacent to a chest and may retain water between the chest cover and the chest. The face mask and the chest cover may heat when activated and may be adapted to evaporate water to create water vapor which may help to break up mucus located within the user's sinuses and throat. The temperature of the heat created by the face mask and the chest cover may be controlled via a first thermostat control and a second thermostat control, respectively.

The invention provides Eubacterium mucilaginosus E11405 and an application thereof. The invention provides Eubacterium mucus E11405, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the Eubacterium mucus E11405 is CGMCC No.31231. The invention further provides a preparation method of the Eubacterium mucus E11405. The inventor of the application studies the effect and mechanism of the Eubacterium mucus E11405 in relieving the mouse colorectal cancer, and the result shows that the Eubacterium mucus E11405 has a remarkable relieving effect on the mouse colorectal cancer, and can be used as a probiotic preparation for relieving the colorectal cancer. The Eubacterium mucilaginosus E11405 provides a new strategy for prevention and treatment of colorectal cancer-based digestive tract tumors, has potential clinical application prospects, and is expected to become an effective medicine for treating colorectal cancer-based digestive tract tumors.

The invention provides a spleen and stomach conditioning factor lactobacillus reuteri obtained by fermenting poria cocos powder. The strain has good acid resistance, cholate resistance and antibacterial ability. The invention further provides a probiotic preparation which has an obvious effect on improving the spleen and the stomach. In addition, the invention also provides a composite preparation composition containing Lactobacillus reuteri, and the composition effectively promotes normal peristalsis and digestion and absorption functions of gastrointestinal tracts by regulating the secretion level of gastrointestinal hormones, enhances the immunity of the organism, protects intestinal mucosa barriers, comprehensively improves the symptoms of weakness of the spleen and the stomach, and improves the overall health level.

This invention relates to the technical field of deep processing of sturgeon by-products, and particularly to a sturgeon tendon peptide with antioxidant and pancreatic lipase inhibitory activities and its preparation method. The preparation method includes the following steps: mixing sturgeon with water and crushing it to form a first slurry; adding Bacillus licheniformis alkaline protease to the first slurry for a first hydrolysis; adding Bacillus subtilis neutral protease to the first hydrolysate for a second hydrolysis; adding a complex enzyme to the second hydrolysate for a third hydrolysis to obtain a sturgeon tendon hydrolysate; filtering the sturgeon tendon hydrolysate to remove impurities to obtain a filtrate, which is then filtered again to retain polypeptides, thus obtaining the sturgeon tendon peptide; wherein the complex enzyme includes pectinase and amylase. Using this method, a sturgeon tendon peptide with high glycosaminoglycan content can be obtained, which exhibits pancreatic lipase inhibitory activity, antioxidant activity, Staphylococcus aureus inhibitory activity, and prebiotic effects that promote the proliferation of Lactobacillus plantarum and Lactobacillus fermentum.

The invention provides a strain of fermentation lactobacillus mucus TG017, and the strain of fermentation lactobacillus mucus TG017 has the effects of reducing uric acid, purine and adenosine. The lactobacillus fermentum is lactobacillus fermentum TG017, is preserved in the China Center for Type Culture Collection on April 10, 2023, has the preservation number of CCTCC NO: M 2023513, and is located in the preservation center of Wuhan University in Hubei China, and the preservation number of the lactobacillus fermentum TG017 is CCTCC NO: M 2023513. The invention further relates to the use of the Lactobacillus mucilaginosus TG017 strain.

The invention relates to the technical field of oral membranes, in particular to a multilayer oral membrane and a preparation method thereof. The invention provides an oral membrane composition, which comprises semeglutide and pharmaceutically acceptable auxiliary materials, and is characterized in that the composition is formed by combining a drug-containing biological adhesion layer and a backing layer, and the backing layer mainly comprises a membrane forming material, a solvent and a plasticizer; the drug-containing biological adhesion layer mainly comprises semeglutide, a film-forming material, an adhesive, a pH regulator, a flavoring agent and a solvent. By preparing the double-layer oral membrane, the semeglutide is administrated through the oral cavity, and after the insoluble or slowly eroded / dissolved backing layer (preventing saliva from dissolving the medicine) and the adhesive layer containing the main medicine are combined together, the one-way delivery of the main medicine can be realized; through experiments, it is accidentally found that when temperature-sensitive materials such as poloxamer are added to be combined with a conventional adhesive for use, the residence time of the medicine in the oral mucosa can be remarkably prolonged, the curative effect of the medicine is improved, and the main mechanism is that after the medicine is administered, in the oral temperature environment, after the medicine makes contact with mucus on the surface of the oral mucosa, the oral mucosa does not adhere to the oral mucosa. And after the entanglement and piling effects among poloxamer micelles are intensified to form gel, the gel and a conventional adhesive are cooperated to improve the adhesion between the oral membrane and the oral mucosa. Besides, the medicine can be removed at any time, blood sugar can be better controlled, T2DM complications can be better reduced, a more ideal taking mode is provided for weight loss patients, and a new administration mode is provided for reducing blood sugar and reducing weight. The prepared oral cavity membrane is small in size, light in weight, thin, convenient to apply, carry and transport, safe and environmentally friendly to use and capable of meeting the requirements of old people and travelers.

The invention relates to the technical field of medical breather pipes, in particular to an adjustable pharyngeal breather pipe which comprises a seaming opening, and a through hole is formed in the seaming opening. The gas conduit comprises a main exhaust passage and an oxygen supply interlayer, a sampling gas passage is arranged in the main exhaust passage, and oxygen flows out from an area between the oxygen supply interlayer and the main exhaust passage; the adjusting assembly comprises an impeller; the cleaning mechanism comprises a clamping plug and is used for automatically adjusting the distance between the sampling gas channel and the oxygen outlet according to the oxygen outlet flow, the larger the oxygen flow is, the larger the distance between the sampling gas channel and the oxygen outlet is, and it is avoided that too much oxygen is inhaled to affect the detection result; meanwhile, mucus and water vapor are unblocked through reciprocating movement of the clamping plug, the sampling air channel is guided through the rolling ring, meanwhile, the water vapor of exhaled air is adsorbed, and the mucus and the water vapor are prevented from blocking the air guide pipe.

The present invention discloses a Bifidobacterium breve strain capable of clearing toxins in the body and its postbiotics, belonging to the technical field of microbial applications. The present invention isolates a Bifidobacterium breve strain ( Bifidobacterium breve ) WZA-BB07 from human feces, and its biological deposit number is: CCTCC NO: M20241530. The strain WZA-BB07 has good effects in degrading endotoxin and enterotoxin. The strain and Lactobacillus mucosae are mixed and fermented to prepare postbiotics. Bifidobacterium breve mainly improves the balance of intestinal flora and inhibits the growth of harmful bacteria. Lactobacillus mucosae helps repair the intestinal barrier through its metabolites during fermentation, enhancing the metabolism and clearance of toxins; extracts of Dendrobium officinale, Lonicera japonica, and Pueraria lobata are added to the fermentation medium, which not only provides rich nutrition for fermentation but also exerts the antioxidant, anti-inflammatory, and intestinal repair-promoting effects of ingredients with both medicinal and edible properties, further enhancing the detoxification ability and overall health effects of the postbiotic product.

The invention belongs to the technical field of probiotics, and particularly relates to fermented lactobacillus mucus BM01 with an effect of relaxing bowel and application of the fermented lactobacillus mucus BM01. A new fermented lactobacillus mucus BM01 strain is separated from excrement of a healthy infant in Guangzhou city, Guangdong province, a zebra fish constipation model is constructed through loperamide hydrochloride, and research finds that the strain can remarkably promote intestinal tract movement, increase the content of in-vivo serotonin and inhibit the enzyme activity of dipeptidyl peptidase-4, so that the constipation of the zebra fish can be inhibited, the constipation of the zebra fish can be inhibited, and the constipation of the zebra fish can be inhibited. Therefore, the bowel relaxing effect is achieved. It is indicated that the BM01 strain can play the bowel relaxing effect through multiple mechanisms, has significant application value, can be used for research and development of drugs for treating constipation, irritable bowel syndrome and other intestinal diseases or development of health care products with the bowel relaxing effect, and can also be used as a feed additive to improve animal intestinal health and reduce disease risks. The culture benefit is improved.

The invention provides an application of lactobacillus mucus B14.32 in traditional Chinese medicine fermentation and an anti-depression traditional Chinese medicine fermentation composition, a microbial fermentation technology is combined with traditional Chinese medicine extraction, and lactobacillus mucus B14.32 and saccharomycetes are used for carrying out two-step fermentation on traditional Chinese medicine with an anti-depression effect to obtain the anti-depression traditional Chinese medicine fermentation composition. The active ingredients of the traditional Chinese medicines are preserved to the maximum extent, the medicine effect is enhanced, the toxicity is reduced, the obtained anti-depression traditional Chinese medicine fermentation composition has the effects of resisting depression and relieving brain inflammation of depression patients, and a safer and more effective treatment scheme is provided for the depression patients.

The invention relates to lactobacillus reuteri HC1602 as well as a fungicide and application thereof, and belongs to the technical field of microorganisms. The lactobacillus reuteri HC1602 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.26890, the preservation date is March 23, 2023, and the address of the preservation institution is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The invention further provides application of the lactobacillus reuteri HC1602 in preparation of products for inhibiting and preventing respiratory syncytial viruses and application of the lactobacillus reuteri HC1602 in preparation of products for reducing cholesterol in blood. The lactobacillus reuteri HC1602 provided by the invention can be used for effectively inhibiting the invasion of RSV (Respiratory Syndrome Virus) to A549 lung cells and improving the survival rate of the A549 cells.

The invention provides a probiotic composition for preventing and / or inhibiting oral pathogens as well as a derivative product, a preparation method and application of the probiotic composition, and belongs to the technical field of oral care. The probiotic composition comprises the following bacterial strains in parts by mass: 90 to 0.45 part of a lactobacillus rhamnosus bacterial strain A2114, 10 to 0.3 part of a plant lactobacillus bacterial strain A2124, 80 to 0.4 part of a pediococcus pentosaceus bacterial strain A2135, 250 to 0.25 part of a lactobacillus reuteri bacterial strain A21350, and 40 to 0.2 part of a plant lactobacillus bacterial strain A2109. The probiotic composition or the metabolite thereof can effectively inhibit oral pathogens such as streptococcus mutans, porphyromonas gingivalis, helicobacter pylori, escherichia coli and staphylococcus aureus. Therefore, the probiotic composition or the metabolite thereof shows a good application prospect in the aspects of preventing and relieving oral problems such as decayed teeth, periodontitis and ozostomia.

The invention discloses a nursing sputum suction device for an intensive care unit. The nursing sputum suction device comprises a sputum suction device body, a control part and a sputum collection barrel. The control part and the sputum collecting barrel are both mounted at the top of the sputum aspirator body; the bottom of the sputum collecting barrel is provided with a notch which is concavely embedded inwards, a cover plate is hinged to the notch, a sealing cavity is formed in the position, located on the periphery of the notch, of the bottom of the sputum collecting barrel, and a heating wire is arranged in the sealing cavity; a plurality of through holes for collecting residual liquid are annularly formed in the liquid collecting cavity; an electric heating element matched with the heating wire is also arranged at the liquid collecting cavity; the heating wire and the nozzle are arranged in the sputum collecting barrel, the stirring effect of bubbles and the heating effect of clear water jointly act on sputum in the sputum collecting barrel, the sputum is fully diluted and purified, and residue and accumulation of the sputum in the sputum collecting barrel are reduced. The heating effect is beneficial for accelerating decomposition of components such as protein and mucus in sputum, so that the sputum is easier to dilute and purify by clear water, and the risk of bacterium breeding is reduced.

The invention discloses an application of probiotics in preparation of a medicine for preventing and / or treating cholestatic liver diseases. The probiotics are selected from one or more of plant lactobacillus Lp-G18, bifidobacterium longum subsp. Longum BL-G301, lactobacillus reuteri LR-G100 and lactobacillus johnsonii LJ-G55. Preferably, the cholestatic liver disease is primary biliary cholangitis.

The invention discloses a method for quantitatively detecting viable bacteria of lactobacillus reuteri, lactobacillus rhamnosus, lactobacillus paracasei and lactobacillus acidophilus. The novel molecular detection target disclosed by the invention has high specificity on target bacteria. The disclosed PMA-qPCR method comprises the steps of target detection, qPCR primer and probe design, qPCR detection system, PMA treatment condition and viable bacteria quantitative standard curve. After qPCR amplification, if a Cq value appears, the dissolution peak is single and the dissolution temperature is consistent with that of a positive sample (only aiming at a dye method), the lactic acid bacteria are identified as target lactic acid bacteria, and the number of viable bacteria can be calculated according to a corresponding standard curve. The method can effectively detect and count viable bacteria of Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei and Lactobacillus acidophilus, has the advantages of rapidness, accuracy, simple operation and the like, and is convenient for food enterprises and inspection institutions to use.

The invention discloses application of fermented lactobacillus mucus capable of prolonging life, resisting aging and resisting oxidation, and belongs to the technical field of functional strains. The preservation numbers of the lactobacillus mucus A21224 and the lactobacillus mucus A21227 are GDMCC No: 62958 and GDMCC No: 62962 respectively, and the lactobacillus mucus A21224, the lactobacillus mucus A21227 and the lactobacillus mucus A21227 are used for The two strains can remarkably prolong the service life of nematodes, have good antioxidant effect and heat stress resistant effect, can prolong the service life of the nematodes by 40% in a strong oxidation environment, and can prolong the service life of the nematodes by 28.57% under the stress of a thermal environment. In addition, the lactobacillus mucus A21224 and the lactobacillus mucus A21227 both show an excellent anti-aging effect in the late stage of the nematodes. Meanwhile, the two strains have certain gastrointestinal fluid-resistant and cholate-resistant effects, can be colonized in intestinal tracts, have no hemolysis phenomenon and are high in safety.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus mucus BU360 with the function of improving uric acid, blood fat and blood glucose metabolism and application of the lactobacillus mucus BU360. The preservation number of the lactobacillus fermentum BU360 provided by the invention is CGMCC (China General Microbiological Culture Collection Center) No.33032. The lactobacillus fermentum BU360 provided by the invention has the advantages that the preservation number is CGMCC No.33032; the lactobacillus mucus BU360 can efficiently degrade guanosine and inosine which are precursor substances for synthesizing uric acid and directly degrade the uric acid, thalli, cell contents and metabolites of the lactobacillus mucus BU360 can inhibit the activity of xanthine oxidase and relieve HUA, and the lactobacillus mucus BU360 can directly degrade cholesterol and inhibit the activity of alpha-glucosidase and alpha-amylase, so that the lactobacillus mucus BU360 can be used for preparing the uric acid. The polypeptide has potential capability of improving blood fat and blood glucose metabolism abnormality, and assists in treatment of HUA; besides, the strain has relatively strong acid-resistant and cholate-resistant characteristics, can smoothly reach the intestinal tract of a human body, has relatively good safety on sensitivity of various antibiotics, and lays a foundation for development of related probiotic products. The lactobacillus mucus BU360 has a wide application prospect in the aspect of preparing products for relieving HUA, improving blood fat and blood glucose metabolism and the like.

The invention discloses a lactobacillus mucus fermentation strain and application thereof, the lactobacillus mucus fermentation strain is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on February 21, 2025, and the preservation number is GDMCCNO: 65936. The feruloyl esterase is separated and screened from white sour soup in Kailing in southeast of Guizhou province, has feruloyl esterase activity, and shows good blood fat reducing and fatty liver treating capabilities in a HepG2 high-fat cell model and a high-fat zebra fish model. The compound has a good prospect in the development of products for preventing or treating hyperlipidemia and fatty liver and relieving obesity.

Systems and methods for treating a patient's mucus hypersecretion condition are disclosed herein. Certain implementations may involve a method for reducing mucus secretion in an upper airway of a patient to treat at least one of post nasal drip or chronic cough. The method may include advancing a treatment delivery portion of an energy-based treatment device into a nostril of the patient. The treatment delivery portion may contact mucosal tissue of the upper airway without piercing the mucosal tissue. The treatment delivery portion may deliver treatment to at least one tissue selected from the group of the mucosal tissue and another tissue underlying the mucosal tissue to modify a property of the at least one tissue and thus treat at least one of post nasal drip or chronic cough in the patient.

The invention discloses a strain of lactobacillus fermentum LF-HF25 obtained by screening sour cucumber, which is preserved in the China Center for Type Culture Collection, the preservation number is CCTCC No.M20241566, the classification name is the lactobacillus fermentum LF-HF25, the preservation date is July 15, 2024, and the preservation address is Wuhan University, China. The lactobacillus fermentum LF-HF25 has the advantages that the preservation number is CCTCC No.M20241566, the classification name is the lactobacillus fermentum LF-HF25, the preservation date is July 15, 2024, and the preservation address is Wuhan University, China. The lactobacillus mucilaginosus LF-HF25 or the metabiotic microbial inoculum prepared from the lactobacillus mucilaginosus LF-HF25 has the functions of dispelling the effects of alcohol, protecting the liver, promoting digestion and nourishing the stomach, also has the effect of improving sleep, and has a wide application prospect.

The invention relates to lactobacillus mucilaginosus and application thereof. Wherein the gene of the molecular marker for fermenting lactobacillus mucus has one of the following nucleotide sequences: (1) a nucleotide sequence as shown in SEQ ID NO: 24; (2) a nucleotide sequence having at least 97%, 98%, 99% or higher homology with the nucleotide sequence as shown in SEQ ID NO: 24; and (3) a nucleotide sequence with one or more nucleotide sequences, such as 1, 2, 3, 4, 5 or more nucleotide substitutions, deletion or insertion, in the nucleotide sequence as shown in SEQ ID NO: 24. The fermented lactobacillus mucus provided by the invention is non-toxic, has good biological characteristics, has good curative effects on prevention and / or treatment of vaginal infection and related diseases, and avoids the problems of increased drug resistance, high recurrence rate and the like caused by use of antibiotic and other antibacterial drugs during treatment of vaginal infection and related diseases.

The invention relates to the technical field of traditional Chinese medicine plasters, in particular to a traditional Chinese medicine ointment for preventing relapse of infantile asthma and a preparation method thereof.The traditional Chinese medicine ointment is characterized by sequentially comprising a protective backing layer, a medicine storage layer, a controlled release film layer and an application bonding layer from top to bottom; the traditional Chinese medicine plaster provided by the invention overcomes the defect that the traditional oral traditional Chinese medicine is easily influenced by a first-pass effect and individual differences through an external transdermal administration mode, can continuously maintain efficient medicine concentration at an application part and realize long-acting slow release, and the synergistic effect of the nano micro-emulsion medicine carrying system and the controlled release film layer can realize the sustained release effect of the traditional Chinese medicine. According to the traditional Chinese medicine plaster disclosed by the invention, the stable release of effective components of the medicine is ensured, the penetration rate of the medicine on a skin barrier is also remarkably improved, so that the treatment depth and the action durability of the plaster are enhanced, and meanwhile, the traditional Chinese medicine plaster aims at the pathological mechanism of infantile asthma, relieves airway inflammation, reduces airway hyperresponsiveness and mucus secretion, and has a remarkable curative effect on infantile asthma. The acute attack frequency of asthma can be obviously reduced, and the remission period is prolonged.

Modular mucosal tissue bioreactors combined with bioartificial mucus provide a high-fidelity, medium-throughput platform for evaluating CF treatments and modeling host-pathogen biology, a stepping stone towards better options for HEMT-nonresponsive patients. Whole lung ex vivo Cystic Fibrosis model system allows for investigation of candidate CF therapies.